BIOMAT Database Logo BIOMAT Database Logo

Effect of 2-amino-6-[(1-methyl-4-nitro-5-imidazolyl)thio]purine (imidazolylthioguanine; B.W. 57-323) on acute leukemia in man. 1960

O S SELAWRY

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D015122 Mercaptopurine An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. 6-Mercaptopurine,1,7-Dihydro-6H-purine-6-thione,6-Mercaptopurine Monohydrate,6-Thiohypoxanthine,6-Thiopurine,6H-Purine-6-thione, 1,7-dihydro-,BW 57-323H,Leupurin,Mecaptopurine Anhydrous,Mercaptopurina Wellcome,Puri-Nethol,Purimethol,Purinethol,6 Mercaptopurine,6 Mercaptopurine Monohydrate,6 Thiohypoxanthine,6 Thiopurine,BW 57 323H,BW 57323H

Related Publications

O S SELAWRY
The metabolism of 2-amino-6-[(1-methyl-4-nitro-5-imidazolyl)thio]purine (B.W. 57-323) in man.
July 1960, Cancer chemotherapy reports,
O S SELAWRY
Effect of 2-amino-6-[(1-methyl-4-nitro-5-imidazoly)thio] purine (B.W. 57-323) on neoplastic disease in man.
July 1960, Cancer chemotherapy reports,
O S SELAWRY
A summary of investigations with 2-amino-6-[(1-methyl-4-nitro-5-imidazolyl)thio]purine (B.W. 57-323) in animals.
July 1960, Cancer chemotherapy reports,
O S SELAWRY
Clinical and hematologic study of 6[(1-methyl-4-nitro-5-imidazolyl)thio]-purine (B.W.57-322) and related compounds.
October 1961, Cancer chemotherapy reports,
O S SELAWRY
The effectiveness of 2-amino-6-[(1-methyl-4-nitro-5-imidazolyl)thio] purine against transplantable mouse leukemia.
July 1960, Cancer chemotherapy reports,
O S SELAWRY
Effect of 6-(1'-methyl-4'-nitro-5'-imidazolyl)-mercaptopurine and 2-amino-6-(1'-methyl-4'-nitro-5'-imidazolyl)-mercaptopurine on the rat litter in utero.
December 1962, Journal of reproduction and fertility,
O S SELAWRY
2-Amino-5-(1-methyl-5-nitro-2-imidazolyl)-1,3, 4-thiadiazole: a new antimicrobial agent.
December 1968, Science (New York, N.Y.),
O S SELAWRY
[Effect of 2-(5-methyl-4-imidazolyl)-1-methylethylamine on histamine receptors].
September 1978, Il Farmaco; edizione scientifica,
O S SELAWRY
Nitroheterocyclic antimicrobial agents. 1-Methyl-2-nitro-5-imidazolyl derivatives.
October 1972, Journal of medicinal chemistry,
O S SELAWRY
Preparation, antimicrobial evaluation, and mutagenicity of [2-hydroxyaryl]-[1-methyl-5-nitro-1H-2-imidazolyl]methanols , [5-tert-butyl-2-methylaminophenyl]-[1-methyl-5-nitro-1H-2-imidazo lyl]me thanol, and [2-hydroxyaryl]-[1-methyl-5-nitro-1H-2-imidazolyl] ketones.
October 1997, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!